Figure 2.
The dynamic changes of serous AFP level over time: AFP dropped to <400 ng/ml after surgical removal of an intrahepatic tumor in June 2019 and sintilimab-bevacizumab biosimilar IBI305–hfIMRT–oxaliplatin combination treatment in February 2022, and continued to decline gradually during the stage of maintenance treatment with sintilimab and bevacizumab biosimilar IBI305.
